Theravance Biopharma
TBPH
TBPH
119 hedge funds and large institutions have $546M invested in Theravance Biopharma in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 49 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
4.37% less ownership
Funds ownership: 95.69% → 91.32% (-4.4%)
16% less capital invested
Capital invested by funds: $653M → $546M (-$106M)
41% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 49
Holders
119
Holding in Top 10
4
Calls
$431K
Puts
$299K
Top Buyers
| 1 | +$4.01M | |
| 2 | +$3.14M | |
| 3 | +$3.12M | |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$3.1M |
| 5 |
SG Americas Securities
New York
|
+$1.25M |
Top Sellers
| 1 | -$31.1M | |
| 2 | -$14.6M | |
| 3 | -$13.4M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.76M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.28M |